The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro

@article{Konrat2020TheAA,
  title={The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro},
  author={Robert Konrat and Henrietta Papp and Val{\'e}ria Szij{\'a}rt{\'o} and Tanja Gesell and G{\'a}bor Nagy and M{\'o}nika Madai and Safia Zeghbib and Anett Kuczmog and Zs{\'o}fia Lanszki and Zsuzsanna Helyes and G{\'a}bor Kemenesi and Ferenc Jakab and Eszter Nagy},
  journal={bioRxiv},
  year={2020}
}
Background The COVID-19 pandemic is an enormous threat for healthcare systems and economies worldwide that urgently demands effective preventive and therapeutic strategies. Unlike the development of vaccines and new drugs specifically targeting SARS-CoV-2, repurposing of approved or clinically tested drugs can provide an immediate solution. Methods We applied a novel computational approach to search among approved and clinically tested drugs from the DrugBank database. Candidates were selected… 
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
TLDR
The extensive functional genomic analysis showed that both infection and treatment with in vitro effective drugs leads to activation of antiviral pathways like NFkB and JAK-STAT, and based on the similarity - and not inverse similarity - between drug and infection-induced gene expression signatures, the in vitro antiviral activity of drugs was predicted.
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
TLDR
The extensive functional genomic analysis showed that both infection and treatment with in vitro effective drugs leads to activation of antiviral pathways like NFkB and JAK-STAT, and based on the similarity—and not inverse similarity—between drug and infection-induced gene expression signatures, the in vitro antiviral activity of drugs was predicted.
A systems‐level study reveals host‐targeted repurposable drugs against SARS‐CoV‐2 infection
TLDR
Using a quantitative systems pharmacology approach, a set of repurposable and investigational drugs are identified as potential therapeutics against COVID-19, showing that several predicted compounds had inhibitory activities in Vero-E6 cells.
DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing
TLDR
This cohort study leveraged EHR data to identify a list of drugs that could be repurposed to improve CO VID-19 outcomes and found 17 drugs were significantly associated with decreased COVID-19 severity.
The Multidirectional Effect of Azelastine Hydrochloride on Cervical Cancer Cells
TLDR
Study demonstrated the multidirectional effects of azelastine on HeLa cells, including anti-proliferative, cytotoxic, autophagic, and apoptotic properties, which were the predominant mechanism of death.

References

SHOWING 1-10 OF 32 REFERENCES
Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2
TLDR
There are an urgent need for antivirals to treat the newly emerged SARS-CoV-2 and a repurposing library of ~3,000 drugs was screened, finding 9 drugs are antiviral in lung cells, 7 of which have been tested in humans, and 3 are FDA approved including Cyclosporine.
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
TLDR
A panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS -CoV-2 infection, and a total of 24 drugs which exhibited antiviral efficacy were found.
Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning
TLDR
A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • Xueting Yao, F. Ye, Dongyang Liu
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
TLDR
It is proposed that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients.
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
TLDR
The results indicate that chloroquine targets a pathway for viral activation that is not active in lung cells and is unlikely to protect against the spread of SARS-CoV-2 in and between patients.
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
TLDR
This study presents an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network.
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
TLDR
This study presents an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network.
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
TLDR
The results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.
...
...